Clinical Trial Update: An Exploratory Study of MT-2990 in Patients With AAV [Phase 1]

View source ↗

Summary

A completed Phase 1 exploratory study of MT-2990 in patients with ANCA-associated vasculitis (AAV).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis

Drugs mentioned

• MT-2990

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV) | Phase 1 | Status: COMPLETED